volved primarily the apoprotein B-containing lipoproteins. No patient showed serum lipoprotein (a) [Lp(a)] <300 mg/L during the acute phase. Lp(a) concentrations correlated significantly with those of apoprotein B, and both values decreased dramatically with the remission of the nephrotic syndrome. Surprisingly, despite the resolution of proteinuria, concentrations of intermediate-density lipoproteins and Lp(a) remained above normal in hypertriglyceridemic patients, suggesting a residual effect of nephrosis in the overall lipoprotein transport. Accumulation of atherogenic remnants should be considered a characteristic of the hyperlipidemia of the nephrotic syndrome, and aggressive treatment to reduce proteinuria is mandatory. (7, 8) ,
and substantial increases might account for the increased frequency of arteriosclerotic vascular disease seen in these patients (9) (10) (11) . Moreover, the approach to managing hyperlipidemia in the nephrotic syndrome is still controversial, but efforts to reduce the serum concentration of atherogenic particles seem prudent (12) .
A weak or absent correlation has been observed between the 24-h urinary excretion and the degree of Patients and Methods
Study Subjects and Samples
The procedures followed were in accordance with the ethical standards of the Hospital de Sant Joan. From 218 patients enrolled according to a previous study (4) , from 1986 to 1992, we included in a follow-up evaluation those patients with normal renal function and more likely to present complete remission from the nephrotic syndrome, i.e., those of age <50 years and with biopsy-proved either minimal change disease (n = 13) or membranous nephropathy (n = 18). The nephrotic syndrome was defined as urinary protein excretion of >3.5 g/24 h and serum albumin concentration <30 g/L; remission was considered to be complete 
Results

Baseline Laboratory Data
No difference in any of the variables measured was observed between patients with minimal change disease and patients with membranous nephropathy. Consequently, data are presented irrespective of the histological diagnosis. We arbitrarily divided patients into two subgroups-those with serum triglyceride concentration below (n = 10) or above (n = 9) 2.05 mmol/L, designated as normotriglyceridemics and hypertriglyceridemics, respectively-with the rationale that different lipoprotein derangement may be present in each group. The baseline clinical and laboratory data for the study population is shown in Table 1 were lower in the overt nephrotic syndrome than in remission ( Table 2) , but no such difference was observed in mean values for serum apo A-I (Fig. 2) . The greater the initial value, the greater the percentage of decrease in remission (r = 0.59, P <0.01). The reduction in Lp(a) concentrations was also highly correlated with the decreases in LDL cholesterol (r = 0.77, P <0.001) and serum apo B (r = 0.85, P <0.001), but no correlation with IDL-cholesterol values was found. 
Density-Gradient Ultracentrifugation
We observed the presence of abnormally abundant material in the IDL region in most patients with active nephrotic syndrome (Fig. 3) . In concordance with the data obtained by preparative ultracentrifugation The hypertriglyceridemic patients also showed a broader apparent LDL peak, probably representing LDL heterogeneity
(24).
More strikingly, we also saw qualitative changes in hypertriglyceridemic patients with active nephrotic syndrome, the highest LDL peak value being in fraction 28 (Fig. 3B) , whereas in the other groups considered, this peak was observed in fraction 26. This accumulation of remnants probably is related to the increased (P <0.001) serum apo E concentrations observed in patients with the nephrotic syndrome (80 ± 30 mg/L); apo E values normalized when the urinary protein excretion remitted (40 ± 20 mg/L vs 46 ± 15 mg/L in controls).
Discussion
Our study conclusively demonstrates that lipoprotein abnormalities associated with the nephrotic syndrome are ameliorated but not completely reversed with the remission of proteinuria. It also indicates that the accumulation of atherogenic remnants derived from the catabolism of triglyceride-rich lipoproteins and Lp(a) is an important characteristic of the dyslipoproteinemia present in nephrotic patients.
We previously obtained (4) data indicating that the increase in apo B-containing lipoproteins associated with the nephrotic syndrome was mediated by a reversible increase in apo B production, with a normal catabolic rate; in light of these new data, however, that conclusion should be reconsidered. In fact, the accumulation of remnants and the increase in apo E concentrations suggest a defect in the lipoprotein removal. Some patients with the nephrotic syndrome are normotriglyceridemic, but others show a moderate hypertriglyceridemia, which, although not uniformly expressed, is associated with minor derangements in lipoprotein lipase and hepatic lipase activities (25) . Recent kinetic studies have shown that the variation in Lp(a) concentrations among individuals is chiefly determined by the rate of Lp(a) production (31) , and the kidney itself has not been reported to participate directly in apo(a) metabolism.
Considering that apo B is common to LDL and Lp(a), perhaps the correlation between the decrease in Lp(a) and LDL cholesterol and in serum apo B indicates that a similar mechanism is responsible for the increased Lp(a) in the nephrotic syndrome. We observed a trend towards higher Lp(a) values in hypertriglyceridemic patients, but the differences did not reach statistical significance.
In conclusion, our observation that lipoprotein abnormalities in the nephrotic syndrome are even more atherogenic than previously thought (4) may reinforce the suggestion that hyperlipidemia in the nephrotic syndrome should be treated aggressively (12) . Moreover, we provide direct evidence that proteinuria is directly linked to the abnormal lipid profile in the nephrotic syndrome, a finding concordant with previous reports that specific treatment of the proteinuria may lessen these lipid abnormalities (14, 15) .
